Hyperion Partners’s CVS Health CVS Stock Holding History

Hyperion Partners’s Portfolio CVS Stock Details CVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,788	Closed	-$207K	–	66
2023 Q1	$207K	Buy	2,788 +42	+2%	+$3.52K	0.19%	63
2022 Q4	$256K	Buy	+2,746	New	+$265K	0.24%	50

Other funds holding CVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Hyperion Partners's CVS Position: Q2 2023 in Review

Hyperion Partners sold out of CVS Health (CVS) in Q2 2023, closing a stake of 2,788 shares — an estimated $207K sold.

Hyperion Partners first reported a position in CVS in Q4 2022 and held it in 2 quarters. The position peaked at $256K in Q4 2022. 2,206 funds tracked by Wall St. Rank hold CVS as of Q2 2023.

Hyperion Partners reported no remaining CVS Health position as of Q2 2023 after selling out during the quarter.
Hyperion Partners sold 2,788 CVS Health shares in Q2 2023, an estimated $207K.
Hyperion Partners first reported a position in CVS Health in Q4 2022 and held it in 2 quarters.
Hyperion Partners's CVS Health position peaked at $256K in Q4 2022.
2,206 funds tracked by Wall St. Rank held CVS Health as of Q2 2023.

Based on Hyperion Partners's 13F filing for Q2 2023, filed 11 Jul 2023.